William A. Wexler - 09 Nov 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Nov 2023, 16:32:54 UTC
Prior SEC filing: 01 Sep 2023
Next SEC filing: 17 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact

Key filing fact

William A. Wexler filed Form 4 for Comera Life Sciences Holdings, Inc. on 14 Nov 2023.

Key facts

This page summarizes William A. Wexler's Form 4 filing for Comera Life Sciences Holdings, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Nov 2023, 16:32.

Change

Previous filing in this sequence was filed on 01 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMRA transaction Derivative

Stock Option (Right to Purchase)

Award

Transaction value: $0
Shares: +75,376
Change %
Price: $0.000000
Shares after: 75,376
Date: 09 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,376
Exercise price: $0.3204
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant.

Footnote F2

In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $10,000. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.